医药翻倍主题基金仅剩一只

Group 1 - The A-share pharmaceutical sector has shown strong performance this year, with related thematic funds achieving significant returns, but there has been a correction since September, leading to profit-taking and only one fund remaining that has doubled in value [1] - From September to the end of November, the pharmaceutical thematic index has decreased by 9.21%, while it had increased by over 18% from January to the end of August [1] - Among 136 pharmaceutical thematic funds, 10 funds had returns exceeding 100% from the beginning of the year to the end of August, while 39 funds had returns over 50% [1] Group 2 - There are 14 pharmaceutical thematic funds with negative net values this year, with 3 funds experiencing declines exceeding 10% [2] - Industry experts remain optimistic about the investment outlook for the pharmaceutical sector, citing factors such as innovation in Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices [2] - The pharmaceutical industry is expected to maintain an overweight position, with investment strategies focusing on innovation, internationalization, and domestic policy benefits [2]